Abstract: Polyacetals comprising a recurring units represented by a formula selected from the group consisting of formula (I) and (II): wherein A comprises at least one acetal group; B is selected from the group consisting of —CH—, —CH(CH3)—, CH2CH—, —CH2C(CH3)—, —CH(CH3)CH—, and —CHCH(CH3)CH(CH3)—; Z is selected from the group consisting of C(O)OR1, C(O)SR1, C(O)NR1R2, and VU; V is a linker group; U is selected from the group consisting of poly(ethyleneimine), poly(propyleneimine), poly(lysine), PAMAM dendrimer, octaamine dendrimer, hexadecaamine dendrimer, enhancer, and targeting receptor; R1 and R2 are each individually selected from the group consisting of hydrogen, C1 to C10 alkyl, and C6 to C10 aryl; D is a linkage selected from the group consisting of carboxylic amide, carboxylic ester, urea, and urethane; and G is selected from the group consisting of C4 to C20 alkyl, C6-C10 aryl, and —(OCH2CH2)n—, where n is in the range of 1 to about 250, are useful in nucleic acid delivery applications.

Abstract: The invention concerns a method of conserving biological prostheses, wherein the method includes the following steps: (a) treating biological prostheses with a solution which contains a mixture of epoxide compounds which are at least in part of different lengths; (b) treating the biological prosthesis treated in accordance with step (a) with an antithrombotic-bearing solution; and (c) possibly storing the prosthesis treated in accordance with step (b) in a sterilising solution. The invention further concerns a biological prosthesis produced in accordance with the method of the invention and a conserving agent.

Abstract: The present invention relates to a new ortho ester-based surfactant, where the hydrophobic and hydrophilic parts are connected by ortho ester linkages to the molecule. The ortho ester has the formula where R is hydrogen or an aliphatic group with 1–7 carbon atoms; R1 is hydrogen or an alkyl group with 1–5 carbon atoms; A1 is an alkyleneoxy group with 2–4 carbon atoms, the number of ethyleneoxy groups being at least 50% of the total number of alkyleneoxy groups; n1 is a number between 1 and 30; R2 is an aliphatic group with 5–22 carbon atoms; A2 is an alkyleneoxy group with 3–4 carbon atoms; n2 is a number between 0–30, provided that when R2 is an aliphatic group with 5–6 carbon atoms n2 is at least 1; R3 is selected from the group consisting of (A1)n1R1, (A2)n2R2 and an alkyl group with 1–6 carbon atoms, where A1, n1, R1, A2, n2 and R2 have the same meaning as mentioned above; or a di- or polycondensate via any of the free hydroxy groups of the ortho ester.

Abstract: Disclosed are methods and compositions for regulating the melanin content of mammalian melanocytes; regulating pigmentation in mammalian skin, hair, wool or fur; treating or preventing various skin and proliferative disorders; by administration of various compounds, including alcohols, diols and/or triols and their analogues.

Abstract: The present invention relates to compositions which comprise a combination a) of one or more glycerol monoalkyl ether(s) of the general formula R—O—CH2—CHOH—CH2OH in which R is a branched or unbranched C3-C18-alkyl group, where the alkyl group can be substituted by one or more hydroxyl and/or C1-C4-alkoxy group(s) and/or the alkyl chain can be interrupted by up to four oxygen atoms, with b) an antioxidant or two or more antioxidants as stabilizer(s), the simultaneous presence of phosphocholines and phosphocholine derivatives being excluded.

Abstract: The field of colonic diagnostic and surgical procedures is hampered by the lack of optimal means available to cleanse the colon. A compromise between convenient, distasteful, solid or low volume, hyperosmotic solutions which cause considerable fluid and electrolyte imbalances in patients and large volume, difficult to consume, iso-osmotic solutions has had to be made heretofore. This invention describes a low volume, hyper-osmotic solution consisting of sulfate salts with and with out polyethylene glycol. Unlike prior art, this composition is useful for the cleansing of the bowel and, in lower volumes, as a laxative, without producing clinically significant changes in bodily function.

Abstract: The present invention relates to compositions and methods for treating infectious diseases and genetic disorders through gene therapy and intracellular delivery of antisense oligonucleotides or other nucleic acid sequences. In particular, compositions and methods using biologically active nononic reverse block copolymers are described. The reverse copolymers have an inner core of polyoxyethylene (POE) that is flanked on either end by polyoxpropylene (POP). The reverse block copolymers have the following formula: wherein “b” represents a number such that the molecular weight of the hydrophobe (C3H6O)b is between approximately 750 and 20,000 Daltons and “a” represents a number such that the percentage of hydrophile (C2H4O)a is between approximately 1% and 90% of the weight of the block copolymer.

Abstract: A polymer comprising recurring units represented by formula (I): wherein X is selected from the group consisting of C(O)OR1, C(O)SR1, C(O)NR1R2, and VZ, where R1 and R2 are each individually selected from the group consisting of hydrogen, C1 to C10 alkyl, and C6 to C10 aryl, where V is a labile linker group, and where Z is selected from the group consisting of poly(ethyleneimine), poly(propyleneimine), poly(lysine), PAMAM dendrimer, octaamine dendrimer, and hexadecaamine dendrimer; and wherein Y is selected from the group consisting of —(CH2)2—, —(CH2)2—O—(CH2)2—, —(CH2)2—O—(CH2)2—, and —(CH2)3—NHC(O)—(CH2)6—C(O)NH—(CH2)3— is useful in nucleic acid delivery applications. Polyacetals of the formula (I) are preferably made by reacting appropriate diols and divinyl ethers. In preferred embodiments, complexes formed between polyacetals of the formula (I) and polynucleotides are useful as transfection reagents.

Abstract: The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Abstract: The invention provides a solid composition of nisoldipine and a mixture of two polyethylene oxides having specific viscosities. The invention also provides a process for manufacturing said composition.

Abstract: Methods and compositions for selectively inactivating viruses in biological compositions, including contacting the composition with an organic solvent and an ethyleneimine oligomer inactivating agent, are disclosed.

Abstract: Disclosed are novel materials separated from Ecklonia cava, a method for extracting and purifying the same, and the use thereof for antioxidants. The method comprises extracting antioxidative ingredients from powdered Ecklonia cava one or more times with an organic solvent; fractionating the antioxidative ingredients one or more times in solvents; and purifying the solvent fractions by chromatography. Superior in scavenging activity and thermal stability, the extract from Ecklonia cava can be used as antioxidants and is suitable in commercialization.

Abstract: A composition comprising, per litre of aqueous solution, from 30 to 350 g polyethylene glycol, from 3 to 20 g of an ascorbic acid component selected form the group consisting of ascorbic acid, a salt of ascorbic acid, or a mixture thereof, an alkali metal or alkaline earth metal sulphate, preferably from 1 to 15 g thereof, and optionally one or more electrolytes selected from sodium chloride, potassium chloride, and sodium hydrogen carbonate, and preferably also comprising flavourings, is effective in cleansing the gut in preparation for a endoscopy, especially colonoscopy. It is safer than conventional sodium phosphate-based gut cleansing compositions, and hence can be used for patients who would be at risk with sodium phosphate-based compositions, and is better tolerated than conventional PEG-based compositions, leading to better patient compliance and enabling effective out-patient use.

Abstract: The invention relates to a pharmaceutical composition comprising a polynucleotide and at least 2% (weight/volume), preferably 2 to 10%, of a nonionic copolymer of formula (I)OH(CH2CH2O)a(CH(CH3)CH2O)a(CH2CH2O)cH, in which a, b, and c are such that the polyoxypropylene portion has a molecular weight of between 1450 and 2050, and the polyoxyethylene portions constitute between 75 and 85% (weight:weight) of the copolymer. The composition is preferably free of cationic lipid or of sodium phosphate. The copolymer is intended to improve the transfer of the polynucleotide into, or the expression of the polynucleotide in, eukaryotic cells. A typical example of a copolymer corresponding to formula (I) is F68. A composition according to the invention is in particular useful in the gene therapy, vaccination and immunotherapy fields.

Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.

Abstract: An apparatus and method for determining the viscosity of the circulating blood of a living being over plural shear rates caused by a decreasing pressure differential by monitoring the changing weight of the blood, or the changing level of a column of blood over time. The apparatus and method utilize a riser, a capillary tube, a collector and a mass detector, such as a precision balance or a load cell, for monitoring the changing weight of a sample of fluid that flows through these components under the influence of the decreasing pressure differential; alternatively, the apparatus and method use a column level detector to monitor the changing level of the column of blood over time.

Abstract: The invention relates to oral care compositions such as toothpaste, gels, tooth powders, mouthwashes, mouth rinses, gums, mouth sprays and lozenges comprising diglycerol. The diglycerol is used as a humectant in the compositions. The compositions may further comprise water, flavoring agents, active compounds, emulsifier, alcohol, sweeteners, thickening agents, surfactants, suspending agents, astringent and toning drug extracts, flavor correctants, abrasives or polishes, deodorizing agents, preservatives, flavoring buffers, whitening agents, wound-healing and inflammation inhibiting substances, colorants, dyes, pigments, abrasives, polishes, antimicrobial agents, pH buffers and other additives and fillers.

Abstract: Disinfectant which has activity towards mycobacteria and comprises (a) 1-(2-ethylhexyl) glycerol ether and (b) one or more aromatic alcohols selected from the group consisting of aryloxyalkanols, oligoalkanol aryl ethers and arylalkanols.

Abstract: A thickener composition containing a reaction product of a hydroxycarboxylic acid selected from the group consisting of tartaric acid, malic acid, citric acid and mixtures thereof, and a fatty alcohol polyglycol ether corresponding to formula I: R1O(CH2CH2O)nH  (I) wherein R1 is an alkyl and/or alkenyl group containing from 6 to 22 carbon atoms, and n is a number from 20 to 150.

Abstract: The invention provides compositions for rapid bowel cleansing comprising a mixture of polyethylene glycol and sodium phosphate(s). The compositions are particularly useful for preparing the bowel prior to surgery or diagnostic procedures such as colonoscopies. The invention further comprises methods for cleansing the bowel using these compositions, and bowel cleansing kits comprising these compositions.

Abstract: A method is disclosed to stabilize compositions comprising airborne viruses, particularly Adenoviruses; and more particularly recombinant Adenoviruses, by adding to the compositions a non-ionic detergent which comprises an alkyl moiety and a polyethylene glycol (PEG). Pharmaceutical and other compositions of Adenoviruses, particularly recombinant Adenoviruses suitable for methods of gene therapy, which comprise such detergents are also disclosed.

Abstract: The creation of a limpid, stable micro-emulsion from liquid lipophilic materials of vegetable origin, specifically, essential oils, using an ecologically optimized solubilizing agent consisting of a mixture of one ethoxylated vegetable oil and at least one supplemental surfactant comprising an anionic surfactant derived from another vegetable oil and/or a non-ionic co-surfactant. The micro-emulsion retains the original active properties of the essential oils in addition to the specific individual properties of the solubilizing agent or the mixture thereof with the lipophilic vegetable materials. Applications: all the applications of essential oils and those conferred by the addition of the specific surfactants.

Abstract: Disclosed are methods and compositions for regulating the melanin content of mammalian melanocytes; regulating pigmentation in mammalian skin, hair, wool or fur; treating or preventing various skin and proliferative disorders; by administration of various compounds, including alcohols, diodls and/or triols and their analogues.

Abstract: An antiseptic/antifungal agent comprising 2,2-dialkyl-1,3-propanediol represented by the formula (I): wherein R1 and R2 can either be identical or different from each other, and both denote an alkyl group with a carbon number of 1-4, and an endermic liniment containing the same. In addition, an endermic liniment containing 3-methyl-3-methoxybutanol and 1,2-pentanediol, and an endermic liniment containing 3-methyl-3-methoxybutanol and 2-phenoxyethanol, is provided.

Abstract: A method comprising administering by ocular route a dose of a glycol ether effective to induce retinal detachment.

Abstract: A topical clotting ointment in which cumin in powder form or in oil form is a blood clotter in combination with an unctuous host substance and one or more infection-specific antiseptics and odorants. Method for manufacture includes processing for suspension of the cumin in the host substance and putting it preferably in a squeezable-tube dispenser (7) having an airtight cap (8).

Abstract: The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Abstract: The present invention relates to compositions which comprise a combination

Abstract: A topical composition for delivering an effective amount of a pharmaceutically acceptable drug, including laureth-4, propylene glycol, dimethylsorbide, and a pharmaceutically acceptable diluent is described as an improved drug delivery composition. Further, a method of transepithelial delivery of a drug to a human by topical application to the skin of a human of a composition including laureth-4, propylene glycol, dimethylsorbide, a pharmaceutically acceptable diluent of water and ethanol and an effective amount of a pharmaceutically acceptable drug has beneficial delivery effects.

Abstract: An antibacterial liquid dish cleaning composition with desirable cleansing and de-staining properties comprising a C8-18 ethoxylated alkyl ether sulfate, two anionic surfactant, a betaine surfactant, a hydroxy containing organic acid, polyethylene glycol, hydrogen peroxide and water.

Abstract: An antibacterial liquid dish cleaning composition with desirable cleansing properties comprising a C8-18 ethoxylated alkyl ether sulfate, two anionic surfactant, a betaine surfactant, a hydroxy containing organic acid, an organic thickener, polyethylene glycol and water.

Abstract: Stable pharmaceutical compositions comprising recombinant adeno-associated virus (AAV) virions are described. The compositions provide protection against loss of recombinant AAV vector genomes and transduceability under conditions such as exposure to cycles of freezing and thawing and storage in glass or polypropylene vials. The compositions comprise recombinant AAV virions in combination with one or more dihydric or polyhydric alcohols, and, optionally, a detergent, such as a sorbitan ester. Also described are methods of using the compositions.

Abstract: The present invention relates to a polyethylene glycol-bound ligand in which polyethylene glycol is bound to a ligand having a binding affinity for a specific receptor or a specific protein (i.e.

Abstract: Stable, biocompatible cosmetic or dermatological oil-in-water emulsions (I), containing fatty acids and alcohols, glycerides, ethoxylated esters, non-polar lipids and consistency components, are new. Cosmetic or dermatological oil-in-water emulsion preparations (I) contain (by weight): (a) 0.1-5% 14-22 C fatty acid(s); (b) 0.2-10% fatty acid mono- and/or diglyceride(s); (c) 0.1-5% ethoxylated fatty acid ester(s); (d) 0.5-10% non-polar lipid(s); (e) 0.5-7.5% fatty alcohol(s); and (f) 0.5-7.5% lipophilic consistency source(s) having a melting point or drop point of at least 30 degrees C. The sum of the contents of (a)-(c) is at most 12% and the lipid phase optionally contains up to 40% (based on this phase) of polar lipids.

Abstract: A method and compositions for reducing post-surgical adhesion formation/reformation in mammals following surgical injury to a body cavity or organs situated therein. The aqueous compositions comprising pentoxifylline and a polyoxyalkylene block copolymer are applied to the injured areas subsequent to surgical injury.

Abstract: An absorbent article, particularly a tampon having additives that reduce toxic shock syndrome toxin (TST-1) production is disclosed. The tampon has a combination of an effective amount of at least one oxygen inhibiting agent and an effective amount of at least one surface active agent applied to: the surface of the absorbent tampon material; the surfaces of the fibers comprising the tampon; to the tampon applicator; or any combination of the foregoing. The effective amounts of the oxygen inhibiting agent and the surface active agent are sufficient to reduce the toxin production at lease about 50%, but do not negatively affect the wearer's normal vaginal flora.

Abstract: An ophthalmic composition which contains a component A consisting of at least one member selected from the group consisting of polyoxyalkylene block copolymers and their derivatives, and a component B consisting of at least one member selected from the group consisting of glycyrrhizic acid and its salts.

Abstract: A liquid mixture is described having a cetane number higher than 40, characterized in that it consists of: a typical diesel gas oil cut having a boiling point ranging from 150 to 380° C. and a density ranging from 0.76 to 0.935 g/ml at 15° C.; one or more compounds selected from dialkyl-polyformals represented by the formula: RO(CH2O)mR wherein R is a CnH2n+1 alkyl chain m is an integer equal to or greater than 2 and less than or equal to 6, n is an integer ranging from 1 to 10, wherein the concentration of said dialkyl-polyformals in the gas oil ranges from 1 to 20% by volume. A process is also described for the production of dialkyl-polyformals, starting from alcohols and/or dialkylformals and formaldehyde in the presence of sulfonic acids optionally substituted.

Abstract: The present invention relates to a compound of the general formula (I) which is a non-hydrolysable analogue of endogenous cannabinoids, which are found to be more potent therapeutic agents as they are more stable, for example, to hydrolytic cleavage in the gastrointestinal tract. The cannabinoid analogues of the invention have a therapeutic value. Therefore, pharmaceutical compositions comprising as active ingredient a therapeutically effective amount of at least one compound of the invention may be prepared. Such compositions may be used as anti-inflammatory, anti-asthmatic, analgetic, hypotensive, antiemetic or anti-spasmodic compositions, and as compositions for treating and/or preventing glaucoma or migraine, or as compositions for relieving symptoms of multiple sclerosis and mood stimulating compositions.

Abstract: An absorbent article having a bodyside liner includes a hydrophilic lotion formulation on the outer bodyfacing surface thereof. The hydrophilic lotion formulation comprises from about 10 to about 90 weight percent of a hydrophilic solvent, from about 5 to about 90 weight percent of a high molecular weight polyethylene glycol, and from about 0 to about 60 weight percent of a fatty alcohol. The hydrophilic lotion formulation has a reduced adverse effect on the absorbent and liquid uptake properties of the liner and the absorbent body when compared to conventional lipophilic or hydrophobic lotion formulations. The hydrophilic lotion formulation acts as a lubricant to reduce the abrasion of the skin caused by the liner and also transfers to the skin to provide improved skin health.

Abstract: An ophthalmic composition which contains a component A consisting of at least one member selected from the group consisting of polyoxyalkylene block copolymers and their derivatives, and a component B consisting of at least one member selected from the group consisting of glycyrrhizic acid and its salts.

Abstract: The application of film-forming compositions to aquatic sites, especially aquatic breeding sites for control of surface-active aquatic breeding insects other than black flies, especially for immature mosquitos, has been found to be enhanced when different compounds than those suggested in the prior art are used. The compounds according to the present invention comprise film-forming chemicals which are biodegradable, nonionic, insoluble or partially soluble in water, and include C6, C7, C8, C9, C10, and C11 alcohol ethoxylates, propoxylates, and/or alkoxylates with an average of one (1) to five (5) moles of ethylene and/or propylene oxide per mole of alcohol, and mixtures thereof. The compositions may be applied directly as liquids or released into the aquatic environment from a carrier, such as a biodegradable, water-erodible, water-soluble or water-dispersible carrier.

Abstract: The present invention relates to methods of treating cardiovascular diseases, dyslipidemia, dyslipoproteinemia, and hypertension comprising administering a composition comprising an ether compound.

Abstract: Activated carbon, as well as compositions and kits comprising the same, are effective for preventing pregnancy and sexually transmitted diseases including HIV.

Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.

Abstract: Methods and compositions for treating or preventing inflammatory diseases such as psoriasis or multiple sclerosis are provided, comprising the step of delivering to the site of inflammation an anti-microtubule agent, or analogue or derivative thereof.

Abstract: Liquid detergent compositions containing from about 1% to about 90% of a surfactant selected from anionic, nonionic, and amphoteric surfactants and mixtures thereof are prepared with a hydrotrope that is a mixture of an alcohol ethoxylate and a polyethylene glycol ether of glycerin. The hydrotrope provides increased foam generation. The use of a polyethylene glycol ether of glycerin and an alpha hydroxy acid in a liquid detergent composition further promotes skin improvement and maintains healthy skin of the person using the detergent.

Abstract: A topical skin protectant formulation containing a barrier cream and an active moiety for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWAs). The topical skin protectant offers a barrier property and an active moiety that serves to neutralize chemical warfare agents into less toxic agents.

Abstract: A topical skin protectant formulation containing a barrier cream and a reactive moiety for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWA's). The topical skin protectant offers a barrier property and a reactive moiety that serves to neutralize chemical warfare agents into less toxic agents.

Abstract: The impact of lipoxin A4 (LXA4) and aspirin-triggered-lipoxins (ATL) was investigated in tumor necrosis factor (TNF&agr;)-initiated neutrophil (PMN) responses in vitro and in vivo using metabolically stable LX analogs. At concentrations as low as 1-10 nM, the LXA4 and ATL analogs each inhibited TNF&agr;-stimulated superoxide anion generation and IL-1&bgr; release by human PMN.